GenVivo

GenVivo is a private, pre-revenue biotech founded in 2015 and headquartered in San Diego, CA. The company is pioneering an in vivo CAR-T therapy approach using its proprietary G-Volve platform, a targeted, non-replicating retrovector system. Led by a seasoned management team with deep biotech and pharmaceutical experience, GenVivo is advancing a pipeline of novel immunotherapies and operates a fully integrated in-house process development and cGMP manufacturing facility. Its mission is driven by a personal commitment to addressing hard-to-treat cancers with more accessible and effective treatments.

G-Volve Platform: a versatile, targeted, non-replicating retrovector system for in vivo gene therapy, designed to generate CAR-T cells inside the patient's body. It incorporates transcriptional and translational regulatory sequences for enhanced efficacy.

GenVivo competes in the rapidly evolving in vivo cell therapy space, facing competition from other biotechs like Capstan Therapeutics, Ensoma, and Umoja Biopharma, as well as large pharma companies investing in next-gen CAR-T. Differentiation hinges on the efficacy, specificity, and manufacturability of its proprietary G-Volve vector platform.